BioStem Technologies is a life sciences corporation, providing technologies with a concentration in pharmaceuticals and regenerative medicine.In March 2020, BioStem Life Sciences announced the buildout of a new 6,100 sq foot state-of-the-art, FDA registered, cGMP facility R&D lab to support the research and development pipeline for Contract Development and Manufacturing business.In August 2018, BioStem Technologies launched a new subsidiary, BioStem Life Sciences, for the development of highest quality placental-based amniotic tissue products.In February 2018, the company signed of a letter of intent to acquire Grupo Impulso De Incentivacion Para Nuevas Tecnologías (GIINT).In February 2018, the company has completed its application to uplist itself to OTCQX market.In January 2018, BioStem planned a US $15 million private placement offering